Show simple item record

dc.contributor.authorDave, R. V.
dc.contributor.authorKim, B.
dc.contributor.authorCourtney, A.
dc.contributor.authorO'Connell, R.
dc.contributor.authorRattay, T.
dc.contributor.authorTaxiarchi, V. P.
dc.contributor.authorKirkham, J. J.
dc.contributor.authorCamacho, E. M.
dc.contributor.authorFairbrother, P.
dc.contributor.authorSharma, N.
dc.contributor.authorCartlidge, C. W. J.
dc.contributor.authorHorgan, K.
dc.contributor.authorMcIntosh, S. A.
dc.contributor.authorLeff, D. R.
dc.contributor.authorVidya, R.
dc.contributor.authorPotter, S.
dc.contributor.authorHolcombe, C.
dc.contributor.authorCopson, E.
dc.contributor.authorColes, C. E.
dc.contributor.authorCutress, R. I.
dc.contributor.authorGandhi, Ashu
dc.contributor.authorKirwan, Cliona C
dc.date.accessioned2021-04-20T08:08:17Z
dc.date.available2021-04-20T08:08:17Z
dc.date.issued2021en
dc.identifier.citationDave RV, Kim B, Courtney A, O'Connell R, Rattay T, Taxiarchi VP, et al. Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study. Br J Cancer. 2021.en
dc.identifier.pmid33767422en
dc.identifier.doi10.1038/s41416-020-01234-4en
dc.identifier.urihttp://hdl.handle.net/10541/623916
dc.description.abstractBackground: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated 'standard' or 'COVID-altered', in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had 'COVID-altered' management. 'Bridging' endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2-9%) using 'NHS Predict'. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of 'COVID-altered' management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41416-020-01234-4en
dc.titleBreast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C studyen
dc.typeArticleen
dc.contributor.departmentThe Nightingale Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UKen
dc.identifier.journalBritish Journal of Canceren
dc.description.noteen]
refterms.dateFOA2021-04-26T09:24:11Z


Files in this item

Thumbnail
Name:
33767422.pdf
Size:
627.0Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record